Infectious Diseases News and Research

RSS

WHO official says agency struggled to find 'right tempo' for release of H1N1 information

The rapid spread of information via the Internet "had a disruptive impact on the handling of the flu pandemic by fanning speculation and rumours," WHO officials said Tuesday on day two of a three-day meeting of external experts tasked with evaluating the WHO's handling of H1N1 (swine flu), Agence France-Presse reports.

15 Apr 2010

University of Pennsylvania School of Medicine ranked #2 among nation's research-oriented medical schools

The University of Pennsylvania School of Medicine has been ranked #2 among the nation's research-oriented medical schools, according to the annual survey by U.S. News & World Report, rising from #3 in last year's survey. The prestigious survey of the nation's 126 fully-accredited medical schools ranked Harvard University in first place and John Hopkins University third.

15 Apr 2010

Opinions: Health and living conditions; H1N1, one year later; global water shortages

Former U.S. Senate Majority Leader Bill Frist (R-Tenn.) and Habitat for Humanity CEO Jonathan Reckford write in an Atlanta Journal-Constitution opinion piece about the need to "address the constant crisis families face daily in deplorable living conditions."

15 Apr 2010

Kenta Biotech presents positive Phase IIa results of panobacumab

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), with all patients completing the treatment for hospital-acquired pneumonia and ventilator-acquired pneumonia caused by P. aeruginosa achieving an effective clearance of pneumonia as well as a 100% survival rate.

15 Apr 2010

WHO discusses shortcomings of its H1N1 response

Keiji Fukuda, the WHO's top influenza expert, on Monday said the organization did not effectively communicate the uncertainties of the H1N1 (swine flu) virus, which led to confusion worldwide, Reuters reports.

15 Apr 2010

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Tapeworm infections of the brain, which can cause epileptic seizures, appear to be increasing in Mexico and bordering southwestern states, Loyola University Health System researchers report.

15 Apr 2010

Drinking tap water is a cost-effective way to fight tooth decay

Tooth decay affects children in the United States more than any other chronic infectious disease, according to the Centers for Disease Control and Prevention (CDC). The CDC states that tooth decay, if left untreated, can cause pain and infections that hinder eating, speaking, playing and learning.

15 Apr 2010

Antibiotic-resistant pneumococci increase rate of bacterial infections in children

In the decade since the introduction of pneumococcal vaccination, significant shifts have occurred in the bacterial strains causing serious pneumococcal infections in children, according to a pair of studies in the April issue of The Pediatric Infectious Disease Journal (www.PIDJ.com). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

13 Apr 2010

New Supramap web-based application to track and stop disease outbreaks

Pathogens can now be easily tracked in time and space as they evolve, an advance that could revolutionize both public health and inform national security in the fight against infectious diseases. Developed by researchers that include scientists at the American Museum of Natural History, Supramap is a new, powerful, web-based application that maps genetic mutations like those among the different strains of avian influenza onto the globe.

13 Apr 2010

Research finding suggests HCV interference with hepcidin synthesis

Iron overload, a common feature of chronic liver disorders, has been linked with oxidative DNA damage, insulin resistance and liver steatosis, and with triggering of hepatic stellate cells thus inducing liver fibrosis.

13 Apr 2010

Drug boosting production of immune system protein worsens TB

An experimental drug that boosts production of the immune system protein interferon worsens tuberculosis (TB) in mice, according to scientists from the National Institutes of Health. The drug acts indirectly by drawing certain immune cells, in which Mycobacterium tuberculosis (M.tb) bacteria thrive, to the lungs. The findings may have potential implications for the care of people infected with TB, the authors note. The research is reported in the May 3 issue of Journal of Clinical Investigation, now available online.

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

Checklist to stay healthy and active during summer season

There are millions of vacation destinations to visit this summer and thousands of sights to see, but there is one surefire way to ruin your trip -- getting sick. Although you may not be thinking about viruses and bacterial infections when you plan your trip, there are a few nasty bugs you should be aware of as you pack your bags.

13 Apr 2010

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that an oral presentation of data for delafloxacin, its lead antibiotic candidate, will be given at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, Institute for Clinical Pharmacodynamics, Ordway Research Institute.

12 Apr 2010

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

GenVec, Inc. announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.

12 Apr 2010

Scientists identify specific mechanism that triggers resistance to vancomycin

A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.

12 Apr 2010

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Optimer Pharmaceuticals, Inc. announced that the top-line results from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection were presented today at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria.

12 Apr 2010

Remediable conditions influence health, development and growth of young children

Pediatric researchers from Boston Medical Center, in partnership with other Children's HealthWatch investigators in Minneapolis, Little Rock, Philadelphia, and Baltimore, have found that the cumulative effects of crowded and unstable housing and uncertain supplies of food and heat act together to decrease the chances of normal growth and development and good physical health among infants and toddlers.

12 Apr 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

Infectious Diseases News and Research

WHO official says agency struggled to find 'right tempo' for release of H1N1 information

University of Pennsylvania School of Medicine ranked #2 among nation's research-oriented medical schools

Opinions: Health and living conditions; H1N1, one year later; global water shortages

Kenta Biotech presents positive Phase IIa results of panobacumab

WHO discusses shortcomings of its H1N1 response

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Drinking tap water is a cost-effective way to fight tooth decay

Antibiotic-resistant pneumococci increase rate of bacterial infections in children

New Supramap web-based application to track and stop disease outbreaks

Research finding suggests HCV interference with hepcidin synthesis

Drug boosting production of immune system protein worsens TB

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Checklist to stay healthy and active during summer season

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

Scientists identify specific mechanism that triggers resistance to vancomycin

Optimer Pharmaceuticals announces results from second Phase 3 clinical study of fidaxomicin

Remediable conditions influence health, development and growth of young children

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

eBook: Advancing infectious disease vaccine development eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News